Cite
HARVARD Citation
Kelley, R. et al. (2022). Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet oncology. 23 (8), pp. 995-1008. [Online].